145 related articles for article (PubMed ID: 37231600)
1. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
Sung J; Musinguzi A; Kadota JL; Baik Y; Nabunje J; Welishe F; Bishop O; Berger CA; Katahoire A; Nakitende A; Nakimuli J; Akello L; Kasidi JR; Kunihira Tinka L; Kamya MR; Sohn H; Kiwanuka N; Katamba A; Cattamanchi A; Dowdy DW; Semitala FC
Int J Tuberc Lung Dis; 2023 Jun; 27(6):458-464. PubMed ID: 37231600
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
[TBL] [Abstract][Full Text] [Related]
4. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
Kadota JL; Musinguzi A; Nabunje J; Welishe F; Ssemata JL; Bishop O; Berger CA; Patel D; Sammann A; Katahoire A; Nahid P; Belknap R; Phillips PPJ; Namusobya J; Kamya M; Handley MA; Kiwanuka N; Katamba A; Dowdy D; Semitala FC; Cattamanchi A
Implement Sci; 2020 Aug; 15(1):65. PubMed ID: 32787925
[TBL] [Abstract][Full Text] [Related]
5. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
6. Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
Yuen CM; Majidulla A; Jaswal M; Safdar N; Malik AA; Khan AJ; Becerra MC; Keshavjee S; Lu C; Hussain H
Clin Infect Dis; 2021 Sep; 73(5):e1135-e1141. PubMed ID: 33289039
[TBL] [Abstract][Full Text] [Related]
7. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
[TBL] [Abstract][Full Text] [Related]
8. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
Chaisson LH; Semitala FC; Nangobi F; Steinmetz S; Marquez C; Armstrong DT; Opira B; Kamya MR; Phillips PPJ; Dowdy DW; Yoon C
AIDS; 2023 Jun; 37(7):1097-1101. PubMed ID: 36779500
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
10. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Jarrett RT; van der Heijden Y; Shotwell MS; Chihota V; Marzinke MA; Chaisson RE; Dooley KE; Churchyard GJ
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0129722. PubMed ID: 36622148
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
[TBL] [Abstract][Full Text] [Related]
13. Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
Hussain H; Jaswal M; Farooq S; Safdar N; Madhani F; Noorani S; Shahbaz SS; Salahuddin N; Amanullah F; Khowaja S; Manzar S; Shah JA; Islam Z; Dahri AA; Shahzad M; Keshavjee S; Becerra MC; Khan AJ; Malik AA
Clin Infect Dis; 2023 Aug; 77(4):638-644. PubMed ID: 37083926
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid and Rifapentine Treatment Eradicates Persistent
Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE
Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955
[TBL] [Abstract][Full Text] [Related]
16. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
[TBL] [Abstract][Full Text] [Related]
17. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
Haas MK; Aiona K; Erlandson KM; Belknap RW
Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Lai WA; Brethour K; D'Silva O; Chaisson RE; Zwerling AA
BMC Public Health; 2022 Dec; 22(1):2292. PubMed ID: 36476206
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
[No Abstract] [Full Text] [Related]
20. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
